Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
Status:
Completed
Trial end date:
2021-03-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if a combination of drugs (these are called:
cyclophosphamide, sirolimus, and mycophenolate mofetil) will protect participants better
against graft vs. host disease (GVHD) after receiving a hematopoietic cell transplant from a
related partially matched (haploidentical) donor. As part of the treatment for their blood
cancer, participants need a hematopoietic cell transplantation (HCT) to improve their chances
of cure. In any HCT, after the stem cell infusion is given, a combination of drugs is needed
to prevent GVHD and facilitate acceptance of the graft.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute